Distinct outcomes with the detection of endemic Burkitt lymphoma, T-cell receptor (TCR) complementarity determining region-3s (CDR3s) matching known anti-HIV TCR CDR3s. This is an ASCO Meeting ...

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing. He wasn’t expecting a fall during an ice storm to lead to a cancer diagnosis. But ...

A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this ...

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). A study of 32 clinical samples from ...

Kieran Healy saw an MSK expert within a week of calling for an appointment. He was quickly diagnosed with a type of lymphoma and joined a clinical trial that gave him access to a new drug. Now cancer ...

– Application is based on data from the Phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival – – This ...

"Typically, patients will present with motor weakness, sensory deficits, and pain in nerve sites affected by NL. The most common nerve sites include the cauda equina nerves, the brachial plexus, the ...